<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265651</url>
  </required_header>
  <id_info>
    <org_study_id>QBGJ398-201</org_study_id>
    <nct_id>NCT04265651</nct_id>
  </id_info>
  <brief_title>Study of Infigratinib in Children With Achondroplasia</brief_title>
  <official_title>Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QED Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QED Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to
      evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor
      receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age
      with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol
      QBGJ398-001) for at least 6 months. The study includes dose escalation with extended
      treatment, and dose expansion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuation</measure>
    <time_frame>Up to 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in annualized height velocity</measure>
    <time_frame>Up to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute height velocity (annualized to cm/year), expressed numerically and as Z-score in relation to ACH and non-ACH tables</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in weight (kg)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in sitting height (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in head circumference (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in upper and lower arm length (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in thigh length (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in knee height (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline in arm span (cm)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of infigratinib by assessment of maximum concentration (Cmax)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of infigratinib by assessment of time-to-maximum concentration (Tmax)</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic parameters by assessing collagen X marker</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic parameters by assessing serum type 1 collagen c-telopeptide</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic parameters by assessing procollagen type 1 N-telopeptide</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pharmacodynamic parameters by assessing bone-specific alkaline phosphatase</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Achondroplasia</condition>
  <arm_group>
    <arm_group_label>Infigratinib 0.016 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infigratinib 0.032 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infigratinib 0.064 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infigratinib 0.128 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:
Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.
Dose Expansion:
Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib 0.016 mg/kg</intervention_name>
    <description>Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
Infigratinib tablets to be administered by mouth.</description>
    <arm_group_label>Infigratinib 0.016 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib 0.032 mg/kg</intervention_name>
    <description>Subsequent cohort dose escalation based on protocol-specific criteria.
Infigratinib tablets to be administered by mouth.</description>
    <arm_group_label>Infigratinib 0.032 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib 0.064 mg/kg</intervention_name>
    <description>Subsequent cohort dose escalation based on protocol-specific criteria.
Infigratinib tablets to be administered by mouth.</description>
    <arm_group_label>Infigratinib 0.064 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib 0.128 mg/kg</intervention_name>
    <description>Subsequent cohort dose escalation based on protocol-specific criteria.
Infigratinib tablets to be administered by mouth.</description>
    <arm_group_label>Infigratinib 0.128 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent by participant or parent(s) or legally authorized
             representative (LAR) and signed informed assent by the participant (when applicable).

          2. Diagnosis of ACH, documented clinically and confirmed by genetic testing.

          3. At least a 6-month period of growth assessment in the PROPEL study (Protocol
             QBGJ398-001) before study entry.

          4. Ambulatory and able to stand without assistance

          5. Able to swallow oral medication.

        Exclusion Criteria:

          1. Hypochondroplasia or short stature condition other than ACH.

          2. In females, having had their menarche.

          3. Height &lt; âˆ’2 or &gt; +2 standard deviations for age and sex based on reference tables on
             growth in children with ACH.

          4. Significant concurrent disease or condition that, in the view of the Investigator
             and/or Sponsor, would confound assessment of efficacy or safety of infigratinib.

          5. Current evidence of corneal or retinal disorder/keratopathy.

          6. History of malignancy.

          7. Currently receiving treatment with agents that are known strong inducers or inhibitors
             of CYP3A4 and medications which increase serum phosphorus and/or calcium
             concentration.

          8. Treatment with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic
             steroids in the previous 6 months or long-term treatment (&gt;3 months) at any time.

          9. Treatment with a C-type natriuretic peptide (CNP) analog, fibroblast growth factor
             (FGF) ligand trap, or treatment targeting FGFR inhibition at any time.

         10. Regular long-term treatment (&gt;3 weeks) with oral corticosteroids (low-dose ongoing
             inhaled steroid for asthma is acceptable).

         11. Treatment with any other investigational product or investigational medical device for
             the treatment of ACH or short stature.

         12. Previous limb-lengthening surgery or guided growth surgery.

         13. Fracture within 6 months of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QED Therapeutics Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>QED Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>QED Therapeutics Senior Medical Director</last_name>
    <phone>1-877-280-5655</phone>
    <email>PROPELstudyinfo@QEDTX.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Murdoch Children's Hosptial</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skeletal dysplasia</keyword>
  <keyword>Endochondral ossification</keyword>
  <keyword>ACH</keyword>
  <keyword>Shortened proximal limbs</keyword>
  <keyword>Fibroblast growth factor receptor 3</keyword>
  <keyword>FGFR3</keyword>
  <keyword>Endochondral bone formation</keyword>
  <keyword>Short-limb disproportionate dwarfism</keyword>
  <keyword>dwarfism</keyword>
  <keyword>Bone disease</keyword>
  <keyword>Bone diseases, developmental</keyword>
  <keyword>Musculoskeletal diseases</keyword>
  <keyword>Osteochondrodysplasia</keyword>
  <keyword>Genetic diseases, inborn</keyword>
  <keyword>Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

